1
Essentials of Pharmacology Respiratory System
Exam Actual Exam 2026/2027 – Complete Exam-
Style Questions with Detailed Rationales | 100%
Verified | Pass Guaranteed – A+ Graded
[SECTION 1: Asthma Pharmacology — Questions 1-20]
Q1: A patient with acute asthma exacerbation is prescribed albuterol. What is the mechanism of
action of this medication?
A. Inhibits the release of histamine from mast cells.
B. Blocks the inflammatory effects of leukotrienes.
C. Stimulates beta-2 adrenergic receptors to cause bronchodilation.
D. Reduces mucosal edema and inflammation.
Correct Answer: C
Rationale: Albuterol is a Short-Acting Beta-Agonist (SABA) that selectively binds to beta-2
receptors in the lungs, leading to smooth muscle relaxation and bronchodilation. This provides
rapid relief of acute bronchospasm. Options A and B describe mast cell stabilizers and
leukotriene modifiers, respectively. Option D describes corticosteroids.
Q2: A nurse is providing discharge teaching for a patient prescribed salmeterol. Which
instruction is most critical?
A. "Use this inhaler for immediate relief of an asthma attack."
B. "Rinse your mouth after using this medication to prevent thrush."
C. "Do not use this medication as a monotherapy; it must be combined with an inhaled
corticosteroid."
D. "Take this medication with food to prevent nausea."
Correct Answer: C
,2
Rationale: Salmeterol is a Long-Acting Beta-Agonist (LABA) which carries a Black Box
warning regarding increased risk of asthma-related death when used without an inhaled
corticosteroid (ICS). It is used for maintenance, not acute relief (Option A). While rinsing the
mouth is important for ICS, it is not the primary safety concern for LABAs alone (Option B).
Q3: Which side effect is most commonly associated with the use of inhaled corticosteroids (ICS)
such as fluticasone?
A. Oral candidiasis (thrush) and dysphonia.
B. Tremors and tachycardia.
C. Hypokalemia.
D. Urinary retention.
Correct Answer: A
Rationale: Inhaled corticosteroids suppress the immune system locally in the oropharynx, which
can lead to fungal infections like oral candidiasis (thrush) and hoarseness (dysphonia). Tremors
and tachycardia (Option B) are typical of beta-agonists. Hypokalemia (Option C) and urinary
retention (Option D) are not standard side effects of ICS.
Q4: A patient with allergic rhinitis and asthma is prescribed montelukast (Singulair). What is the
most important teaching point regarding this medication?
A. It is a fast-acting bronchodilator.
B. Monitor for behavioral changes, including agitation or depression.
C. It must be taken via a metered-dose inhaler.
D. It increases the risk of infection.
Correct Answer: B
Rationale: Montelukast carries a Black Box warning for neuropsychiatric events, including
agitation, aggression, depression, and suicidal ideation. Patients and caregivers should be
instructed to monitor for mood changes. It is not a bronchodilator (Option A) nor is it typically
administered via MDI (Option C).
,3
Q5: What is the primary mechanism of action of mast cell stabilizers like cromolyn sodium?
A. Bronchodilation via beta-2 stimulation.
B. Inhibition of mast cell degranulation to prevent release of histamine and leukotrienes.
C. Blocking the action of leukotrienes on smooth muscle.
D. Reducing eosinophil count in the airways.
Correct Answer: B
Rationale: Mast cell stabilizers prevent the release of inflammatory mediators (histamine,
leukotrienes) from mast cells, thereby preventing the early and late phases of the asthmatic
response. They are not bronchodilators (Option A). Option C describes leukotriene modifiers.
Option D describes monoclonal antibodies.
Q6: Which medication is classified as a leukotriene receptor antagonist?
A. Omalizumab (Xolair).
B. Zafirlukast (Accolate).
C. Fluticasone (Flovent).
D. Cromolyn (Intal).
Correct Answer: B
Rationale: Zafirlukast blocks leukotriene receptors, preventing bronchoconstriction and
inflammation. Omalizumab (Option A) is an anti-IgE antibody. Fluticasone (Option C) is a
corticosteroid. Cromolyn (Option D) is a mast cell stabilizer.
Q7: A patient with moderate persistent asthma is prescribed a combination inhaler containing
fluticasone and salmeterol (Advair). What is the rationale for combining these medications?
A. To provide immediate relief for acute attacks.
B. To reduce the risk of LABA-associated side effects by combining with an ICS.
C. To allow the patient to stop using the SABA.
D. To eliminate the need for spacers.
, 4
Correct Answer: B
Rationale: Combining an Inhaled Corticosteroid (ICS) with a Long-Acting Beta-Agonist
(LABA) provides both anti-inflammatory action and long-term bronchodilation. The ICS
component mitigates the risk of asthma-related death associated with LABA monotherapy. It
does not replace SABA for acute attacks (Option A).
Q8: Omalizumab (Xolair) is indicated for which type of asthma?
A. Exercise-induced bronchospasm.
B. Mild intermittent asthma.
C. Moderate-to-severe persistent allergic asthma.
D. Cough-variant asthma.
Correct Answer: C
Rationale: Omalizumab is a monoclonal antibody that binds to IgE, indicated for patients with
moderate-to-severe persistent allergic asthma that is not controlled by inhaled corticosteroids. It
is not indicated for mild or exercise-induced forms (Options A and B).
Q9: A nurse administers zileuton (Zyflo). The nurse understands that this drug works by:
A. Blocking leukotriene receptors.
B. Inhibiting the synthesis of leukotrienes.
C. Stimulating beta-2 receptors.
D. Reducing IgE levels.
Correct Answer: B
Rationale: Unlike other leukotriene modifiers which block receptors, zileuton inhibits 5-
lipoxygenase, the enzyme responsible for synthesizing leukotrienes. This makes it a synthesis
inhibitor. Option A describes drugs like montelukast.
Essentials of Pharmacology Respiratory System
Exam Actual Exam 2026/2027 – Complete Exam-
Style Questions with Detailed Rationales | 100%
Verified | Pass Guaranteed – A+ Graded
[SECTION 1: Asthma Pharmacology — Questions 1-20]
Q1: A patient with acute asthma exacerbation is prescribed albuterol. What is the mechanism of
action of this medication?
A. Inhibits the release of histamine from mast cells.
B. Blocks the inflammatory effects of leukotrienes.
C. Stimulates beta-2 adrenergic receptors to cause bronchodilation.
D. Reduces mucosal edema and inflammation.
Correct Answer: C
Rationale: Albuterol is a Short-Acting Beta-Agonist (SABA) that selectively binds to beta-2
receptors in the lungs, leading to smooth muscle relaxation and bronchodilation. This provides
rapid relief of acute bronchospasm. Options A and B describe mast cell stabilizers and
leukotriene modifiers, respectively. Option D describes corticosteroids.
Q2: A nurse is providing discharge teaching for a patient prescribed salmeterol. Which
instruction is most critical?
A. "Use this inhaler for immediate relief of an asthma attack."
B. "Rinse your mouth after using this medication to prevent thrush."
C. "Do not use this medication as a monotherapy; it must be combined with an inhaled
corticosteroid."
D. "Take this medication with food to prevent nausea."
Correct Answer: C
,2
Rationale: Salmeterol is a Long-Acting Beta-Agonist (LABA) which carries a Black Box
warning regarding increased risk of asthma-related death when used without an inhaled
corticosteroid (ICS). It is used for maintenance, not acute relief (Option A). While rinsing the
mouth is important for ICS, it is not the primary safety concern for LABAs alone (Option B).
Q3: Which side effect is most commonly associated with the use of inhaled corticosteroids (ICS)
such as fluticasone?
A. Oral candidiasis (thrush) and dysphonia.
B. Tremors and tachycardia.
C. Hypokalemia.
D. Urinary retention.
Correct Answer: A
Rationale: Inhaled corticosteroids suppress the immune system locally in the oropharynx, which
can lead to fungal infections like oral candidiasis (thrush) and hoarseness (dysphonia). Tremors
and tachycardia (Option B) are typical of beta-agonists. Hypokalemia (Option C) and urinary
retention (Option D) are not standard side effects of ICS.
Q4: A patient with allergic rhinitis and asthma is prescribed montelukast (Singulair). What is the
most important teaching point regarding this medication?
A. It is a fast-acting bronchodilator.
B. Monitor for behavioral changes, including agitation or depression.
C. It must be taken via a metered-dose inhaler.
D. It increases the risk of infection.
Correct Answer: B
Rationale: Montelukast carries a Black Box warning for neuropsychiatric events, including
agitation, aggression, depression, and suicidal ideation. Patients and caregivers should be
instructed to monitor for mood changes. It is not a bronchodilator (Option A) nor is it typically
administered via MDI (Option C).
,3
Q5: What is the primary mechanism of action of mast cell stabilizers like cromolyn sodium?
A. Bronchodilation via beta-2 stimulation.
B. Inhibition of mast cell degranulation to prevent release of histamine and leukotrienes.
C. Blocking the action of leukotrienes on smooth muscle.
D. Reducing eosinophil count in the airways.
Correct Answer: B
Rationale: Mast cell stabilizers prevent the release of inflammatory mediators (histamine,
leukotrienes) from mast cells, thereby preventing the early and late phases of the asthmatic
response. They are not bronchodilators (Option A). Option C describes leukotriene modifiers.
Option D describes monoclonal antibodies.
Q6: Which medication is classified as a leukotriene receptor antagonist?
A. Omalizumab (Xolair).
B. Zafirlukast (Accolate).
C. Fluticasone (Flovent).
D. Cromolyn (Intal).
Correct Answer: B
Rationale: Zafirlukast blocks leukotriene receptors, preventing bronchoconstriction and
inflammation. Omalizumab (Option A) is an anti-IgE antibody. Fluticasone (Option C) is a
corticosteroid. Cromolyn (Option D) is a mast cell stabilizer.
Q7: A patient with moderate persistent asthma is prescribed a combination inhaler containing
fluticasone and salmeterol (Advair). What is the rationale for combining these medications?
A. To provide immediate relief for acute attacks.
B. To reduce the risk of LABA-associated side effects by combining with an ICS.
C. To allow the patient to stop using the SABA.
D. To eliminate the need for spacers.
, 4
Correct Answer: B
Rationale: Combining an Inhaled Corticosteroid (ICS) with a Long-Acting Beta-Agonist
(LABA) provides both anti-inflammatory action and long-term bronchodilation. The ICS
component mitigates the risk of asthma-related death associated with LABA monotherapy. It
does not replace SABA for acute attacks (Option A).
Q8: Omalizumab (Xolair) is indicated for which type of asthma?
A. Exercise-induced bronchospasm.
B. Mild intermittent asthma.
C. Moderate-to-severe persistent allergic asthma.
D. Cough-variant asthma.
Correct Answer: C
Rationale: Omalizumab is a monoclonal antibody that binds to IgE, indicated for patients with
moderate-to-severe persistent allergic asthma that is not controlled by inhaled corticosteroids. It
is not indicated for mild or exercise-induced forms (Options A and B).
Q9: A nurse administers zileuton (Zyflo). The nurse understands that this drug works by:
A. Blocking leukotriene receptors.
B. Inhibiting the synthesis of leukotrienes.
C. Stimulating beta-2 receptors.
D. Reducing IgE levels.
Correct Answer: B
Rationale: Unlike other leukotriene modifiers which block receptors, zileuton inhibits 5-
lipoxygenase, the enzyme responsible for synthesizing leukotrienes. This makes it a synthesis
inhibitor. Option A describes drugs like montelukast.
